Miyoshi myopathy, a form of inherited myopathy, is a group of diseases characterized by progressive muscle weakness and atrophy. The disease is associated with dysfunction of muscle fibers, which leads to decreased physical activity and a deterioration in the quality of life of patients. Miyoshi myopathy belongs to the category of myotonic disorders, which are caused by mutations in genes responsible for the structure and function of muscle tissue. The main manifestations of the disease include muscle weakness, increased fatigue, and difficulty performing daily physical activities. The progression of symptoms may vary from patient to patient, but in most cases, the disease has clearly defined clinical characteristics.
History of the disease and interesting historical facts
Miyoshi myopathy was first described in 1965 by Japanese physician Tadeo Miyoshi. In his research, he identified patients with characteristic clinical manifestations, such as weakness in the limb muscles and specific changes in the electromyogram. Over time, it was established that this disease is hereditary. Interestingly, other forms of myopathy have been discovered in different regions of the world, but Miyoshi myopathy has become one of the most studied due to its unique genetic and clinical features.
Epidemiology
There is evidence that Miyoshi myopathy occurs in one in 100,000 people, making this pathology quite rare. Epidemiological studies show that the prevalence of myopathy may vary depending on the region and ethnicity. It has been established that males predominate among patients, which may be due to the hereditary nature of the disease, which is associated with gender. In some populations, the frequency of occurrence can reach 1:50,000.
Genetic predisposition to this disease
Miyoshi myopathy is caused by mutations in the DMD gene, which is responsible for the synthesis of dystrophin, a protein important for maintaining the integrity of muscle cells. About 60% cases of the disease are associated with mutations in this gene. In addition, recent studies have also found links to other genes, such as ANO5, which may affect the modulation of clinical manifestations. Inheritance of this disease is recessive and can manifest itself in both carriers and people without obvious symptoms, but with a positive genetic test.
Risk factors for the development of this disease
Risk factors that contribute to the development of Miyoshi myopathy include:
- Heredity in families with similar diseases.
- Gender: the disease is observed in men 2-3 times more often than in women.
- The influence of certain chemicals at the cellular level that disrupt muscle tissue metabolism.
- The presence of comorbidities such as diabetes or thyroid disease may increase the risk of myopathy progression.
Diagnosis of this disease
Diagnosis of Miyoshi myopathy is based on a comprehensive approach. The main symptoms of the disease include:
- Muscle weakness, especially in the proximal groups.
- Fatigue during physical activity.
- Impaired reflexes, which may manifest as a slow reaction.
For more accurate diagnostics, various laboratory and radiological studies are used:
- Electromyography (EMG) helps assess muscle function and identify abnormalities.
- A blood test to measure creatine kinase (CK) levels, which are often elevated in muscle diseases.
- Muscle tissue biopsy for histological analysis.
- Genetic testing to detect mutations in specific genes.
In the differential diagnosis, it is important to exclude other myopathies and neurological disorders such as amyotrophic lateral sclerosis (ALS) and myasthenia gravis.
Treatment
Treatment of Miyoshi myopathy is complex and should be individualized for each patient. Depending on the stage of the disease, the following methods may be used:
- General treatment including physical therapy to improve muscle strength and functional ability.
- Pharmacological treatment aimed at slowing the progression of the disease and relieving symptoms. In case of manifestations of the inflammatory process, corticosteroids are prescribed.
- Surgical treatment may be indicated in cases of complex contractures or associated orthopedic problems.
- Other treatments such as electrical muscle stimulation, massage and orthopedic devices to improve quality of life.
List of medications used to treat this disease
Drugs that may be used to treat Miyoshi myopathy include:
- Corticosteroids: prednisolone, methylprednisolone.
- Immunosuppressants: methotrexate, azathioprine.
- Therapy aimed at improving metabolism: coenzyme Q10, L-carnitine.
Disease monitoring
Disease monitoring involves regular assessments of the patient's condition, taking into account key indicators such as muscle strength, activity level, and quality of life. The prognosis for Miyoshi myopathy can vary depending on the severity of the disease and the timeliness of treatment. Complications may include disability or the need for ongoing medical care in the medium to long term.
Age-related features of the disease
Miyoshi myopathy may have different age-specific features depending on the age at which the disease manifests itself. In childhood, the disease may be more severe, while in older patients, symptoms may be less pronounced, but the progression of the disease may be smoother and with fewer episodes of exacerbation.
Questions and Answers
- What is Miyoshi myopathy? Miyoshi myopathy is a hereditary disorder characterized by muscle weakness and progressive muscle atrophy.
- What genetic mutations are associated with Miyoshi myopathy? The main mutations are associated with the DMD gene, which is responsible for dystrophin proteins.
- What are the symptoms of Miyoshi myopathy? The main symptoms include muscle weakness, fatigue and difficulty moving.
- How is Miyoshi myopathy diagnosed? Diagnosis includes electromyography, muscle biopsy and genetic testing.
- Is there a treatment for Miyoshi myopathy? Treatment includes physical therapy, medications, and, if necessary, surgery.
